Wall Street brokerages expect ICU Medical, Inc. (NASDAQ:ICUI) to announce earnings per share (EPS) of $1.28 for the current quarter, Zacks reports. Two analysts have provided estimates for ICU Medical’s earnings, with the lowest EPS estimate coming in at $1.16 and the highest estimate coming in at $1.40. ICU Medical posted earnings of $1.65 per share during the same quarter last year, which would indicate a negative year over year growth rate of 22.4%. The firm is expected to announce its next quarterly earnings results after the market closes on Thursday, November 5th.
On average, analysts expect that ICU Medical will report full year earnings of $6.27 per share for the current financial year, with EPS estimates ranging from $6.19 to $6.34. For the next year, analysts forecast that the company will post earnings of $7.30 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow ICU Medical.
ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $1.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.41. ICU Medical had a net margin of 6.61% and a return on equity of 9.77%. The company had revenue of $303.40 million for the quarter, compared to the consensus estimate of $283.37 million. During the same period last year, the firm posted $1.99 EPS. The company’s revenue for the quarter was down 2.8% on a year-over-year basis.
In other ICU Medical news, Director Elisha W. Finney sold 790 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $190.00, for a total transaction of $150,100.00. Following the transaction, the director now owns 1,483 shares of the company’s stock, valued at approximately $281,770. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert S. Swinney sold 277 shares of the business’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $202.22, for a total transaction of $56,014.94. Following the sale, the director now owns 22,782 shares in the company, valued at $4,606,976.04. The disclosure for this sale can be found here. Insiders have sold a total of 24,067 shares of company stock valued at $4,716,070 in the last quarter. 10.90% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICUI. The Manufacturers Life Insurance Company boosted its stake in ICU Medical by 2.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 27,571 shares of the medical instruments supplier’s stock valued at $5,563,000 after purchasing an additional 553 shares in the last quarter. Profund Advisors LLC acquired a new stake in shares of ICU Medical in the second quarter valued at $215,000. Invesco Ltd. lifted its holdings in shares of ICU Medical by 18.4% in the first quarter. Invesco Ltd. now owns 114,383 shares of the medical instruments supplier’s stock valued at $23,079,000 after buying an additional 17,763 shares during the period. Two Sigma Advisers LP boosted its stake in ICU Medical by 3.4% during the first quarter. Two Sigma Advisers LP now owns 24,500 shares of the medical instruments supplier’s stock valued at $4,943,000 after buying an additional 800 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in ICU Medical by 3.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 23,099 shares of the medical instruments supplier’s stock worth $4,257,000 after acquiring an additional 860 shares during the period. Hedge funds and other institutional investors own 92.37% of the company’s stock.
NASDAQ ICUI traded down $2.50 during trading hours on Wednesday, reaching $190.30. The company’s stock had a trading volume of 84,966 shares, compared to its average volume of 153,777. The business has a 50-day simple moving average of $190.38 and a 200 day simple moving average of $193.20. ICU Medical has a 52 week low of $158.01 and a 52 week high of $236.51. The stock has a market cap of $3.98 billion, a PE ratio of 49.95 and a beta of 0.67.
About ICU Medical
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in vascular therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency connectors; SwabCap disinfecting caps; Tego hemodialysis connectors; NovaCath and SuperCath peripheral intravenous (IV) catheters; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs.
Recommended Story: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.